ZA200704251B - Methods and compositions using PDE4 modulators for treatment and management of central nervous injury - Google Patents

Methods and compositions using PDE4 modulators for treatment and management of central nervous injury

Info

Publication number
ZA200704251B
ZA200704251B ZA200704251A ZA200704251A ZA200704251B ZA 200704251 B ZA200704251 B ZA 200704251B ZA 200704251 A ZA200704251 A ZA 200704251A ZA 200704251 A ZA200704251 A ZA 200704251A ZA 200704251 B ZA200704251 B ZA 200704251B
Authority
ZA
South Africa
Prior art keywords
compositions
management
treatment
methods
central nervous
Prior art date
Application number
ZA200704251A
Other languages
English (en)
Inventor
Jerome B Zeldis
Faleck Herbert
Donald C Manning
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of ZA200704251B publication Critical patent/ZA200704251B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200704251A 2004-10-28 2005-10-26 Methods and compositions using PDE4 modulators for treatment and management of central nervous injury ZA200704251B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62380304P 2004-10-28 2004-10-28

Publications (1)

Publication Number Publication Date
ZA200704251B true ZA200704251B (en) 2008-11-26

Family

ID=36319648

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200704251A ZA200704251B (en) 2004-10-28 2005-10-26 Methods and compositions using PDE4 modulators for treatment and management of central nervous injury

Country Status (14)

Country Link
US (1) US20060106085A1 (de)
EP (1) EP1811992A2 (de)
JP (1) JP2008518924A (de)
KR (1) KR20070085454A (de)
CN (1) CN101309585A (de)
AR (1) AR052223A1 (de)
AU (1) AU2005302523A1 (de)
BR (1) BRPI0518062A (de)
CA (1) CA2585423A1 (de)
IL (1) IL182825A0 (de)
MX (1) MX2007005040A (de)
PE (1) PE20061167A1 (de)
WO (1) WO2006050057A2 (de)
ZA (1) ZA200704251B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
JP2009512711A (ja) * 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
SI2231640T1 (sl) * 2008-01-24 2012-09-28 Merck Patent Gmbh Beta-aminokislinski derivati za zdravljenje diabetesa
EP2663292B9 (de) * 2011-01-10 2017-11-08 Celgene Corporation Orale dosierungsformen von cyclopropancarbonsäure {[2- (1s) -1- (3-ethoxy-4-methoxy-phenyl] -2-methansulfonyl-ethyl} -3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amid
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
US10011611B2 (en) 2015-08-14 2018-07-03 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
CA3127357A1 (en) * 2019-01-23 2020-07-30 Path Therapeutics, Inc. Methods of treating epilepsy via phosphodiesterase 4 (pde4) inhibition
US11999694B2 (en) 2021-10-29 2024-06-04 Sensorium Therapeutics, Inc. Delivery of therapeutic alkaloid compounds

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US570302A (en) * 1896-10-27 Weighing-machine
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4215114A (en) * 1976-11-12 1980-07-29 The Upjohn Company Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
RO118291B1 (ro) * 1993-11-30 2003-04-30 Searle & Co Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5801195A (en) * 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5658940A (en) * 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
ATE418536T1 (de) * 1996-08-12 2009-01-15 Celgene Corp Neue immunotherapeutische mittel und deren verwendung in der reduzierung von cytokinenspiegel
ATE238052T1 (de) * 1997-07-31 2003-05-15 Celgene Corp Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
DK1064277T3 (da) * 1998-03-16 2005-10-17 Celgene Corp 2-(2,6-dioxopiperidin-3-yl)isoindolinderivater, deres fremstilling og deres anvendelse som inhibitorer af inflammatoriske cytokiner
SE9803710L (sv) * 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
ES2250121T3 (es) * 1999-03-18 2006-04-16 Celgene Corporation 1-oxo- y 1,3-dioxoisoindolinas y su empleo en composiciones farmaceuticas para la reduccion de niveles de las citocinas inflamatorias.
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20040038874A1 (en) * 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain

Also Published As

Publication number Publication date
KR20070085454A (ko) 2007-08-27
WO2006050057A3 (en) 2008-07-10
AR052223A1 (es) 2007-03-07
CA2585423A1 (en) 2006-05-11
JP2008518924A (ja) 2008-06-05
MX2007005040A (es) 2007-06-19
AU2005302523A1 (en) 2006-05-11
PE20061167A1 (es) 2006-11-08
IL182825A0 (en) 2007-09-20
US20060106085A1 (en) 2006-05-18
WO2006050057A2 (en) 2006-05-11
BRPI0518062A (pt) 2008-10-28
CN101309585A (zh) 2008-11-19
EP1811992A2 (de) 2007-08-01

Similar Documents

Publication Publication Date Title
ZA200704890B (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
ZA200704251B (en) Methods and compositions using PDE4 modulators for treatment and management of central nervous injury
IL178788A0 (en) Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
EP1737453A4 (de) Verfahren zur verwendung immunmodulatorischer verbindungen und diese enthaltende zusammensetzungen zur behandlung und versorgung von hautkrankheiten oder störungen
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
EP1773826A4 (de) C-met-modulatoren und anwendungsverfahren
EP1881823A4 (de) Zusammensetzungen und verfahren zur behandlung von augenleiden
GB2423928B (en) Methods and compositions for treating pain
GB2421260B (en) Well treating compositions for slow release of treatment agents and methods of using the same
ZA200700918B (en) Compositions and methods for treating eye disorders and conditions
IL183115A0 (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
EP1809272A4 (de) Verfahren und zusammensetzungen zur behandlung von schäden durch freie radikale
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
EP1699431A4 (de) Zusammensetzungen zur behandlung von ohrerkrankungen und anwendungsverfahren
EP1802321A4 (de) Zusammensetzungen und verfahren zur modulierung von pgc-1-alpha zur behandlung neurologischer krankheiten und erkrankungen
IL176453A0 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
EP1742635A4 (de) Substituierte organoschwefelverbindungen und verfahren zu ihrer verwendung
IL175426A0 (en) Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders
IL181777A0 (en) Gpr43 and modulators thereof for the treatment of metabolic-related disorders
HK1104800A1 (en) Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
GB2448442B (en) Well treating compositions for slow release of treatment agents and methods of using the same
EP1718329A4 (de) Verfahren zur behandlung von hauterkrankungen
EP1660114A4 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen der extrazellulären matrix
EP1711054A4 (de) Verfahren und zusammensetzungen für die behandlung von schmerzhaften leiden